Cingulate Inc. (CINGW) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cingulate Inc.
Address
1901 West 47th Place
Kansas City, KS 66205
United States of America (the)
Phone
913 942 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
December 08, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Shane J. Schaffer | Co-Founder, Chief Executive Officer & Chairman of the Board | 794,374 | 1975 |
| Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer | 206,313 | 1964 |
| Jennifer L. Callahan | Executive VP, CFO & Secretary | 619,505 | 1971 |
| Raul R. Silva | Co-Founder, Executive Vice President & Chief Science Officer | 0 | 1958 |
| Downey Bryan Wade | Executive VP & Chief Commercial Officer | 0 | 1972 |
| Thomas Dalton | Vice President of Investor & Public Relations | 0 | N/A |
Description
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.
